Protein Synthesis Inhibitors

Bacteria assemble proteins on a 70S ribosome built from a 30S and a 50S subunit; human ribosomes are 80S with different subunit architecture. This structural gap is the entire basis of selective toxicity for this drug family — the antibiotic binds a bacterial-specific ribosomal site and either misreads or halts translation, while human ribosomes are structurally unrecognized by the drug. Because the target is the machinery of protein production itself rather than a single enzyme, this class reaches a very wide range of bacteria, but the same structural resemblance between bacterial and human mitochondrial ribosomes (a relic of mitochondria's bacterial ancestry) explains why some off-target effects, such as bone marrow suppression, still occur at high or prolonged exposure.

30S Subunit Agents

Aminoglycosides (gentamicin, tobramycin, amikacin) bind the 30S subunit and cause misreading of the genetic code, producing nonfunctional proteins and a bactericidal, concentration-dependent kill: a higher peak concentration kills more organisms, rather than time above a threshold mattering most. They also exhibit a post-antibiotic effect, meaning bacterial suppression continues even after the drug concentration falls below the level needed to inhibit growth. Together, these two properties are the pharmacologic rationale for extended-interval (once-daily) dosing: a large single dose maximizes peak-dependent killing, the post-antibiotic effect covers the trough period, and the drug-free interval allows renal tubular cells time to clear accumulated drug, which lowers nephrotoxicity risk without sacrificing efficacy. The defining toxicities are nephrotoxicity (accumulation in renal proximal tubule cells), ototoxicity and vestibular toxicity (irreversible accumulation in inner ear structures causing hearing loss or disequilibrium), and neuromuscular blockade (a rarer risk, more relevant with rapid infusion or in patients with myasthenia gravis). Because the therapeutic window sits close to the toxic range, aminoglycosides are among the few antibiotics where drug concentration monitoring is standard practice, though specific numeric targets are not covered here.

Tetracyclines (doxycycline, minocycline, tigecycline) also bind the 30S subunit, blocking attachment of incoming transfer RNA and halting chain elongation; they are bacteriostatic. Their defining chemical quirk is chelation: divalent and trivalent cations (calcium, magnesium, iron, aluminum) bind the drug and prevent absorption, so dairy products, antacids, and iron supplements taken close in time to the dose blunt effectiveness. Photosensitivity is common, raising sunburn risk. Esophagitis and esophageal ulceration can occur if a capsule is taken lying down or without adequate water, since the drug can lodge against the esophageal wall. Tetracyclines are avoided in pregnancy and in young children because the drug binds to calcium in developing bone and teeth, causing permanent tooth discoloration and potential effects on bone growth.

50S Subunit Agents

Macrolides (azithromycin, clarithromycin, erythromycin) bind the 50S subunit and block translocation of the growing peptide chain; they are generally bacteriostatic, though effect can be cidal at high concentrations against certain organisms. Notable concerns include QT interval prolongation (a class-wide risk, relevant with other QT-prolonging drugs or in patients with electrolyte disturbances), gastrointestinal upset from motilin receptor agonism (erythromycin in particular stimulates gut motility, which is occasionally used therapeutically as a prokinetic), and CYP450 enzyme interactions — clarithromycin and erythromycin are meaningful CYP3A4 inhibitors, raising levels of many co-administered drugs, while azithromycin has minimal CYP interaction and is often preferred when interactions are a concern.

Clindamycin binds the 50S subunit and is valued for anaerobic coverage and skin and soft tissue infections, including some methicillin-resistant staphylococcal strains. It carries a strong, well-documented association with Clostridioides difficile infection, more so than most other antibiotic classes, because it disrupts normal gut flora broadly.

Linezolid, an oxazolidinone binding the 50S subunit, retains activity against resistant gram-positive organisms such as MRSA and vancomycin-resistant enterococci. Its notable risks accumulate with duration of therapy: myelosuppression (thrombocytopenia in particular), and peripheral and optic neuropathy with prolonged courses, which may not fully reverse. Linezolid is also a weak, reversible monoamine oxidase inhibitor, creating a risk of serotonin syndrome when combined with serotonergic drugs such as SSRIs, SNRIs, or certain other agents.

Chloramphenicol, largely of historical and teaching interest in many settings, binds the 50S subunit and is remembered for two severe toxicities: gray baby syndrome in neonates, whose immature hepatic glucuronidation cannot clear the drug, leading to circulatory collapse, and aplastic anemia, a rare but often fatal bone marrow failure that can occur independent of dose.

Bactericidal, Bacteriostatic, and Monitoring

Aminoglycosides are bactericidal; tetracyclines, macrolides, clindamycin, and chloramphenicol are generally bacteriostatic; linezolid varies by organism. In practice, a competent immune system clears bacteria that a bacteriostatic drug has merely stopped from multiplying, so the distinction changes little for most infections in most patients — it matters more in specific situations such as endocarditis or profound neutropenia, where cidal activity is preferred. What matters more consistently across this class is organ-specific toxicity monitoring: renal function and hearing for aminoglycosides, cardiac rhythm and drug interactions for macrolides, bowel pattern for clindamycin, and blood counts and neurologic exam for linezolid.

Nursing Considerations

Core priorities include assessing baseline renal and auditory function before and during aminoglycoside therapy, spacing tetracyclines away from dairy and cation-containing supplements, counseling on sun protection with tetracyclines, monitoring cardiac rhythm and reviewing the medication list for interacting drugs with macrolides, watching for new-onset diarrhea with clindamycin, and monitoring blood counts and asking about neurologic symptoms with extended linezolid use, including screening for serotonergic drug combinations. Patient education should also cover completing the full prescribed course even after symptoms improve, since stopping early allows surviving organisms with partial resistance to rebound and spread — a theme that recurs across this entire drug class regardless of which ribosomal subunit is targeted.